Advantages of Nanoparticles over Conventional Dosage in

Cancer Treatment

Over the past several decades, the development and application of engineered nanoparticles to more
effectively treat cancer have witnessed significant advancements.
We expect precisely engineered nanoparticles to emerge as the next-generation platform for site-specific
cancer therapy and several other biomedical applications.

Conventional Drug Delivery Systems Have Some Significant Disadvantages

Drug resistance

Lack of selectivity

Lack of drug solubility

Dynamic changes of cancer cells

Serious side effects of chemotherapy

Poor targeting of heterogenic tumours

Small amount of drug reaches the cancer cells

Nonspecific targeting of conventional delivery

Inability of the drug to enter the core of tumours, resulting in impaired treatment with reduced
dose and low survival rate

Nanoparticles show tremendous promise in their ability to selectively target cancer cells without
significantly damaging healthy tissues. Drug-loaded nanoparticles evade the efflux mechanism and
maintain high concentration within tumour cells, thereby avoiding the development of resistance.

Nanoparticle-based Drug Delivery Systems are Superior in Many Ways

Entry into tissues at the molecular level

Increased drug localisation and cellular uptake

Cancer diagnosis and treatment applications

Feasibility to programme nanoparticles for recognising cancerous cells

Selective and accurate drug delivery, and avoiding interaction with healthy cells

Direct and selective targeting of the drug to cancerous cells (both active and passive targeting)

Larger surface area with modifiable optical, electronic, magnetic and biologic properties vis- vis
macroparticles

Assisting therapeutic agents to pass through biologic barriers, mediate molecular interactions and
identify molecular changes

Nanoparticles have been modified and enhanced to enable the delivery of drugs across the bloodbrain
barrier (BBB) as well as improved upon to create polyethylene glycol (PEG) modified (PEGylated)
nanoparticles with a prolonged blood circulation time. Targeting ligands (such as small organic molecules,
peptides, antibodies and nucleic acids) have been added to the surface of nanoparticles to specifically
target cancerous cells by selectively binding to the receptors over-expressed on their surface.
Multiple types of therapeutic drugs and/or diagnostic agents (such as contrast agents) could be delivered
using the same carrier to enable combination therapy to overcome multidrug resistance and achieve realtime determination of treatment efficacy.
We expect precisely engineered nanoparticles to emerge as the next-generation platform for site-specific
cancer therapy and several other biomedical applications.
For more information about the use of Nanoparticles and their applications in cancer treatment, check out
our report on Nanoparticle Drug Delivery Systems for Cancer Treatment.

About Aranca:
Aranca is a leading provider of high quality, customized and cost effective research and analytics to global
clients. Founded in UK in 2003, Aranca has a global presence including in the US, Europe and Middle East,
and a state-of-the-art delivery center in Mumbai, India.
Our research solutions are structured around four complementary business lines: Investment Research,
Business Research, Valuation and Advisory Services and Intellectual Property Research.
Over the years, Aranca has become a trusted partner to over 1500 global organizations including Fortune
500 companies, SMBs, investment banks, brokerage firms, asset management firms, consulting firms, PE
and VC firms, law firms, government bodies, trade associations and universities.